Avise analytics Reinitiates Coverage on Bioxytran, Inc. (OTCQB: BIXT)

Avise Analytics reinitiate coverage on Bioxytran, Inc. (OTCQB:BIXT) with a fair valuation of $2.71 per share. Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia.